This webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Breast and Ovarian Cancer, collectively known as Women’s Health Cancers.

The second part of the 2012 NCCN Case Manager and Medical Director Program™ webinar series is on the topics of metastatic melanoma, acute myeloid leukemia, cancer survivorship, and techniques for telephonic case managers.

The second part of the 2012 NCCN Case Manager and Medical Director Program™ webinar series is on the topics of metastatic melanoma, acute myeloid leukemia, cancer survivorship, and techniques for telephonic case managers.

The second part of the 2012 NCCN Case Manager and Medical Director Program™ webinar series is on the topics of metastatic melanoma, acute myeloid leukemia, cancer survivorship, and techniques for telephonic case managers.

The second part of the 2012 NCCN Case Manager and Medical Director Program™ webinar series is on the topics of metastatic melanoma, acute myeloid leukemia, cancer survivorship, and techniques for telephonic case managers.

This webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Bladder, Kidney, and Prostate Cancers.

This webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Bladder, Kidney, and Prostate Cancers.

This webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Bladder, Kidney, and Prostate Cancers.

This webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Bladder, Kidney, and Prostate Cancers.

This webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Bladder, Kidney, and Prostate Cancers.